The size of the Asia Pacific Atrial Fibrillation Surgery Market is predicted to grow USD 427.35 million by 2026 from USD 193.26 million in 2021, registering a CAGR of 17.2% during the forecast period 2021 to 2026.
The APAC atrial fibrillation surgery market is primarily driven by a year-on-year increase in the incidence of atrial fibrillation. According to the Centers for Disease Control and Prevention (CDC), the prevalence of Atrial Fibrillation is expected to vary from 2.7 million to 6.1 million people. By 2030, this figure is expected to reach $12.1 million, representing considerable growth for the APAC article fibrillation industry.
The market's growth pace is accelerated by the rising popularity of more minor invasive treatments. In addition, rising healthcare expenditures are fueling the market's demand. Because the method for atrial fibrillation surgery is inexpensive, there has been a significant increase in the number of people who require it. In addition, there have been significant technical improvements in atrial fibrillation surgery, boosting the patient's cure rate. Growing obesity and heart disease rates across the region are driving the atrial fibrillation industry.
Additionally, heart disease is one of the leading causes of death worldwide. As a consequence of a changing lifestyle, the number of people who suffer from it increases exponentially. Therefore, the market for minimally invasive surgeries is predicted to grow due to benefits such as reduced surgical discomfort, damage, hospital stay, and faster recovery.
Increasing challenges in real-time applications will hamper the expansion of the atrial fibrillation surgery market in this area. The exorbitant cost of therapeutic procedures is further eroding the need for atrial fibrillation. Market challenges occur during 2020-2025 due to a lack of public awareness of the process, the lack of advanced technology in a few countries, and a shortage of experienced labor to operate on patients suffering from atrial fibrillation. In addition, infection and bleeding may occur where the catheters were implanted during atrial fibrillation ablation. Vascular damage, damage to the heart valves, strokes, and heart attacks are all possibilities.
This research report on the Asia-Pacific Atrial Fibrillation Surgery Market has been segmented and sub-segmented into the following categories:
By Surgical Procedure:
By Product:
By Country:
Geographically, Asia Pacific is predicted to be the fastest-growing market because of the senior population at high risk of heart disease. In addition, Asia Pacific countries have more flexible and business-friendly regulatory regimes. It's because less stringent laws and data requirements are so prevalent.
China's atrial fibrillation surgery market will continue to rise at a healthy rate because of the large patient pool and increasing healthcare spending. In nations like China and India, the growth is attributed to a large population of older adults at a high risk of heart disease. The expanding patient pool in the region and the presence of significant players are both contributing to this rise. With a growing elderly population, Asia Pacific's demand for the studied market is likely to rise in the future.
During the forecast period, China is expected to have the largest share of the Asia-Pacific market. A large patient population, an increase in healthcare costs, lower death rates, and positive outcomes from atrial fibrillation devices are only a few of the elements that influenced the region's growth over the evaluation period.
Japan's atrial fibrillation surgery market will likely grab significant market share in expanding healthcare infrastructure, hastening the changeover.
KEY MARKET PLAYERS
Promising companies leading the Asia Pacific Atrial Fibrillation Surgery Market profiled in the Report are Biosense Webster, Inc., Boston Scientific Corporation, St. Jude Medical, Inc., Articure, Inc., Medtronic, Inc., Cardima, Inc. Cardiofocus, Inc. and Biotronik SE & Co.,
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemiology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Surgical Procedure
5.1.1 Introduction
5.1.2 Catheter Ablation Procedures
5.1.3 Surgical Ablation/Maze Procedures
5.1.4 Y-o-Y Growth Analysis, By Surgical Procedure
5.1.5 Market Attractiveness Analysis, By Surgical Procedure
5.1.6 Market Share Analysis, By Surgical Procedure
5.2 Product
5.2.1 Introduction
5.2.2 Catheter Ablation Device
5.2.3 Surgical Ablation Device
5.2.4 Y-o-Y Growth Analysis, By Product
5.2.5 Market Attractiveness Analysis, By Product
5.2.6 Market Share Analysis, By Product
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Surgical Procedure
6.1.3.3 By Product
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Surgical Procedure
6.1.4.3 By Product
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Surgical Procedure
6.1.5.3 By Product
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
6.7 Rest of APAC
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Medtronic, Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Biosense Webster, Inc.
8.3 Boston Scientific CorporationInternational
8.4 St. Jude Medical, Inc.
8.5 Cardiofocus, Inc.
8.6 Atricure, Inc.
8.7 Carima, Inc.
8.8 Ncontact, Inc.
8.9 Biotroik Se & Co.Kg
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
